The transplantation of stem cells may have a therapeutic effect on the pathogenesis and progression of neurodegenerative disorders. In the present study, we transplanted human mesenchymal stem cells (MSCs) into the lateral ventricle of a triple transgenic mouse model of Alzheimer's disease (3xTg-AD) at the age of eight months. We evaluated spatial reference and working memory after MSC treatment and the possible underlying mechanisms, such as the influence of transplanted MSCs on neurogenesis in the subventricular zone (SVZ) and the expression levels of a 56 kDa oligomer of amyloid β (Aβ*56), glutamine synthetase (GS) and glutamate transporters (Glutamate aspartate transporter (GLAST) and Glutamate transporter-1 (GLT-1)) in the entorhinal and prefrontal cortices and the hippocampus. At 14 months of age we observed the preservation of working memory in MSC-treated 3xTg-AD mice, suggesting that such preservation might be due to the protective effect of MSCs on GS levels and the considerable downregulation of Aβ*56 levels in the entorhinal cortex. These changes were observed six months after transplantation, accompanied by clusters of proliferating cells in the SVZ. Since the grafted cells did not survive for the whole experimental period, it is likely that the observed effects could have been transiently more pronounced at earlier time points than at six months after cell application.

Department of Neuroscience 2nd Faculty of Medicine Charles University Prague 150 06 Czech Republic

Department of Neuroscience Institute of Experimental Medicine Academy of Sciences of the Czech Republic Prague 142 20 Czech Republic

Functional Neuroanatomy Laboratory Department of Neuroscience Faculty of Medicine the University of the Basque Country 48940 Leioa Spain

Zobrazit více v PubMed

Blurton-Jones M., Laferla F.M. Pathways by which Aβ facilitates tau pathology. Curr. Alzheimer Res. 2006;3:437–448. doi: 10.2174/156720506779025242. PubMed DOI

Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science. 2002;297:353–356. doi: 10.1126/science.1072994. PubMed DOI

Nistico R., Pignatelli M., Piccinin S., Mercuri N.B., Collingridge G. Targeting synaptic dysfunction in Alzheimer’s disease therapy. Mol. Neurobiol. 2012;46:572–587. doi: 10.1007/s12035-012-8324-3. PubMed DOI

Pozueta J., Lefort R., Shelanski M.L. Synaptic changes in Alzheimer’s disease and its models. Neuroscience. 2013;251:51–65. doi: 10.1016/j.neuroscience.2012.05.050. PubMed DOI

Pratico D., Trojanowski J.Q. Inflammatory hypotheses: Novel mechanisms of Alzheimer’s neurodegeneration and new therapeutic targets? Neurobiol. Aging. 2000;21:441–445; discussion 451–443. doi: 10.1016/S0197-4580(00)00141-X. PubMed DOI

Dantuma E., Merchant S., Sugaya K. Stem cells for the treatment of neurodegenerative diseases. Stem Cell Res. Ther. 2010;1 doi: 10.1186/scrt37. PubMed DOI PMC

Lee H.J., Lee J.K., Lee H., Carter J.E., Chang J.W., Oh W., Yang Y.S., Suh J.G., Lee B.H., Jin H.K., et al. Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer’s disease mouse model through modulation of neuroinflammation. Neurobiol. Aging. 2012;33:588–602. doi: 10.1016/j.neurobiolaging.2010.03.024. PubMed DOI

Lee J.K., Jin H.K., Bae J.S. Bone marrow-derived mesenchymal stem cells reduce brain amyloid-β deposition and accelerate the activation of microglia in an acutely induced Alzheimer’s disease mouse model. Neurosci. Lett. 2009;450:136–141. doi: 10.1016/j.neulet.2008.11.059. PubMed DOI

Bae J.S., Jin H.K., Lee J.K., Richardson J.C., Carter J.E. Bone marrow-derived mesenchymal stem cells contribute to the reduction of amyloid-β deposits and the improvement of synaptic transmission in a mouse model of pre-dementia Alzheimer’s disease. Curr. Alzheimer Res. 2013;10:524–531. doi: 10.2174/15672050113109990027. PubMed DOI

Lee J.K., Jin H.K., Bae J.S. Bone marrow-derived mesenchymal stem cells attenuate amyloid β-induced memory impairment and apoptosis by inhibiting neuronal cell death. Curr. Alzheimer Res. 2010;7:540–548. doi: 10.2174/156720510792231739. PubMed DOI

Shin J.Y., Park H.J., Kim H.N., Oh S.H., Bae J.S., Ha H.J., Lee P.H. Mesenchymal stem cells enhance autophagy and increase β-amyloid clearance in Alzheimer disease models. Autophagy. 2014;10:32–44. doi: 10.4161/auto.26508. PubMed DOI PMC

Nikolic W.V., Hou H., Town T., Zhu Y., Giunta B., Sanberg C.D., Zeng J., Luo D., Ehrhart J., Mori T., et al. Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular β-amyloid deposits in Azheimer mice. Stem Cells Dev. 2008;17:423–439. doi: 10.1089/scd.2008.0018. PubMed DOI PMC

Fan X., Sun D., Tang X., Cai Y., Yin Z.Q., Xu H. Stem-cell challenges in the treatment of Alzheimer’s disease: A long way from bench to bedside. Med. Res. Rev. 2014;34:957–978. doi: 10.1002/med.21309. PubMed DOI

Marei H.E., Farag A., Althani A., Afifi N., Ahmed A.E., Lashen S., Rezk S., Pallini R., Casalbore P., Cenciarelli C. Human olfactory bulb neural stem cells expressing hNGF restore cognitive deficit in Alzheimer’s disease rat model. J. Cell. Physiol. 2015;230:116–130. doi: 10.1002/jcp.24688. PubMed DOI

Ryu J.K., Cho T., Wang Y.T., McLarnon J.G. Neural progenitor cells attenuate inflammatory reactivity and neuronal loss in an animal model of inflamed AD brain. J. Neuroinflamm. 2009;6:39. doi: 10.1186/1742-2094-6-39. PubMed DOI PMC

Chen W.W., Blurton-Jones M. Concise review: Can stem cells be used to treat or model Alzheimer’s disease? Stem Cells. 2012;30:2612–2618. doi: 10.1002/stem.1240. PubMed DOI PMC

Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., Muller F.J., Loring J.F., Yamasaki T.R., Poon W.W., Green K.N., LaFerla F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 2009;106:13594–13599. doi: 10.1073/pnas.0901402106. PubMed DOI PMC

Blurton-Jones M., Spencer B., Michael S., Castello N.A., Agazaryan A.A., Davis J.L., Muller F.J., Loring J.F., Masliah E., LaFerla F.M. Neural stem cells genetically-modified to express neprilysin reduce pathology in alzheimer transgenic models. Stem Cell Res. Ther. 2014;5:46. doi: 10.1186/scrt440. PubMed DOI PMC

Wu S., Sasaki A., Yoshimoto R., Kawahara Y., Manabe T., Kataoka K., Asashima M., Yuge L. Neural stem cells improve learning and memory in rats with Alzheimer’s disease. Pathobiology. 2008;75:186–194. doi: 10.1159/000124979. PubMed DOI

Zhang W., Wang G.M., Wang P.J., Zhang Q., Sha S.H. Effects of neural stem cells on synaptic proteins and memory in a mouse model of Alzheimer’s disease. J. Neurosci. Res. 2014;92:185–194. doi: 10.1002/jnr.23299. PubMed DOI

Zhang W., Wang P.J., Sha H.Y., Ni J., Li M.H., Gu G.J. Neural stem cell transplants improve cognitive function without altering amyloid pathology in an APP/PS1 double transgenic model of Alzheimer’s disease. Mol. Neurobiol. 2014;50:423–437. doi: 10.1007/s12035-014-8640-x. PubMed DOI

Forostyak S., Jendelova P., Kapcalova M., Arboleda D., Sykova E. Mesenchymal stromal cells prolong the lifespan in a rat model of amyotrophic lateral sclerosis. Cytotherapy. 2011;13:1036–1046. doi: 10.3109/14653249.2011.592521. PubMed DOI

Forostyak S., Jendelova P., Sykova E. The role of mesenchymal stromal cells in spinal cord injury, regenerative medicine and possible clinical applications. Biochimie. 2013;95:2257–2270. doi: 10.1016/j.biochi.2013.08.004. PubMed DOI

Laroni A., Novi G., Kerlero de Rosbo N., Uccelli A. Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system. J. Neuroimmune Pharmacol. 2013;8:1062–1076. doi: 10.1007/s11481-013-9456-6. PubMed DOI

Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular Aβ and synaptic dysfunction. Neuron. 2003;39:409–421. doi: 10.1016/S0896-6273(03)00434-3. PubMed DOI

Amemori T., Ermakova I.V., Buresova O., Zigova T., Racekova E., Bures J. Brain transplants enhance rather than reduce the impairment of spatial memory and olfaction in bulbectomized rats. Behav. Neurosci. 1989;103:61–70. doi: 10.1037/0735-7044.103.1.61. PubMed DOI

Sterniczuk R., Antle M.C., Laferla F.M., Dyck R.H. Characterization of the 3× Tg-AD mouse model of Alzheimer’s disease: Part 2. Behavioral and cognitive changes. Brain Res. 2010;1348:149–155. doi: 10.1016/j.brainres.2010.06.011. PubMed DOI

Lacor P.N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., Viola K.L., Klein W.L. Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J. Neurosci. 2007;27:796–807. doi: 10.1523/JNEUROSCI.3501-06.2007. PubMed DOI PMC

Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-β protein assembly in the brain impairs memory. Nature. 2006;440:352–357. doi: 10.1038/nature04533. PubMed DOI

Lesne S.E., Sherman M.A., Grant M., Kuskowski M., Schneider J.A., Bennett D.A., Ashe K.H. Brain amyloid-β oligomers in ageing and Alzheimer’s disease. Brain. 2013;136:1383–1398. doi: 10.1093/brain/awt062. PubMed DOI PMC

Reed M.N., Hofmeister J.J., Jungbauer L., Welzel A.T., Yu C., Sherman M.A., Lesne S., LaDu M.J., Walsh D.M., Ashe K.H., et al. Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol. Aging. 2011;32:1784–1794. doi: 10.1016/j.neurobiolaging.2009.11.007. PubMed DOI PMC

Ferreira S.T., Klein W.L. The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease. Neurobiol. Learn. Mem. 2011;96:529–543. doi: 10.1016/j.nlm.2011.08.003. PubMed DOI PMC

Liu P., Kemper L.J., Wang J., Zahs K.R., Ashe K.H., Pasinetti G.M. Grape seed polyphenolic extract specifically decreases Aβ*56 in the brains of Tg2576 mice. J. Alzheimers Dis. 2011;26:657–666. doi: 10.1016/j.jalz.2010.05.1792. PubMed DOI

Scherzer-Attali R., Farfara D., Cooper I., Levin A., Ben-Romano T., Trudler D., Vientrov M., Shaltiel-Karyo R., Shalev D.E., Segev-Amzaleg N., et al. Naphthoquinone-tyrptophan reduces neurotoxic Aβ*56 levels and improves cognition in Alzheimer’s disease animal model. Neurobiol. Dis. 2012;46:663–672. doi: 10.1016/j.nbd.2012.03.005. PubMed DOI

Zahs K.R., Ashe K.H. β-amyloid oligomers in aging and Alzheimer’s disease. Front. Aging Neurosci. 2013;5:28. doi: 10.3389/fnagi.2013.00028. PubMed DOI PMC

Behrens P.F., Franz P., Woodman B., Lindenberg K.S., Landwehrmeyer G.B. Impaired glutamate transport and glutamate-glutamine cycling: Downstream effects of the huntington mutation. Brain. 2002;125:1908–1922. doi: 10.1093/brain/awf180. PubMed DOI

Coulter D.A., Eid T. Astrocytic regulation of glutamate homeostasis in epilepsy. Glia. 2012;60:1215–1226. doi: 10.1002/glia.22341. PubMed DOI PMC

Guo Y., Duan W., Li Z., Huang J., Yin Y., Zhang K., Wang Q., Zhang Z., Li C. Decreased GLT-1 and increased SOD1 and HO-1 expression in astrocytes contribute to lumbar spinal cord vulnerability of SOD1-G93A transgenic mice. FEBS Lett. 2010;584:1615–1622. doi: 10.1016/j.febslet.2010.03.025. PubMed DOI

Le Prince G., Delaere P., Fages C., Lefrancois T., Touret M., Salanon M., Tardy M. Glutamine synthetase (GS) expression is reduced in senile dementia of the alzheimer type. Neurochem. Res. 1995;20:859–862. doi: 10.1007/BF00969698. PubMed DOI

Minkeviciene R., Ihalainen J., Malm T., Matilainen O., Keksa-Goldsteine V., Goldsteins G., Iivonen H., Leguit N., Glennon J., Koistinaho J., et al. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J. Neurochem. 2008;105:584–594. doi: 10.1111/j.1471-4159.2007.05147.x. PubMed DOI

Robinson S.R. Neuronal expression of glutamine synthetase in Alzheimer’s disease indicates a profound impairment of metabolic interactions with astrocytes. Neurochem. Int. 2000;36:471–482. doi: 10.1016/S0197-0186(99)00150-3. PubMed DOI

Timmer N.M., Herbert M.K., Claassen J.A., Kuiperij H.B., Verbeek M.M. Total glutamine synthetase levels in cerebrospinal fluid of Alzheimer’s disease patients are unchanged. Neurobiol. Aging. 2015;36:1271–1273. doi: 10.1016/j.neurobiolaging.2014.12.010. PubMed DOI

Wilson J.M., Shaw C.A. Late appearance of glutamate transporter defects in a murine model of ALS-parkinsonism dementia complex. Neurochem. Int. 2007;50:1067–1077. doi: 10.1016/j.neuint.2006.09.017. PubMed DOI

Oddo S., Caccamo A., Kitazawa M., Tseng B.P., LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol. Aging. 2003;24:1063–1070. doi: 10.1016/j.neurobiolaging.2003.08.012. PubMed DOI

Rohn T.T., Vyas V., Hernandez-Estrada T., Nichol K.E., Christie L.A., Head E. Lack of pathology in a triple transgenic mouse model of Alzheimer’s disease after overexpression of the anti-apoptotic protein Bcl-2. J. Neurosci. 2008;28:3051–3059. doi: 10.1523/JNEUROSCI.5620-07.2008. PubMed DOI PMC

Bobkova N.V., Poltavtseva R.A., Samokhin A.N., Sukhikh G.T. Therapeutic effect of mesenchymal multipotent stromal cells on memory in animals with Alzheimer-type neurodegeneration. Bull. Exp. Biol. Med. 2013;156:119–121. doi: 10.1007/s10517-013-2293-z. PubMed DOI

Chang K.A., Kim H.J., Joo Y., Ha S., Suh Y.H. The therapeutic effects of human adipose-derived stem cells in Alzheimer’s disease mouse models. Neurodegener. Dis. 2014;13:99–102. doi: 10.1159/000355261. PubMed DOI

Salem A.M., Ahmed H.H., Atta H.M., Ghazy M.A., Aglan H.A. Potential of bone marrow mesenchymal stem cells in management of Alzheimer’s disease in female rats. Cell Biol. Int. 2014;38:1367–1383. doi: 10.1002/cbin.10331. PubMed DOI

Yun H.M., Kim H.S., Park K.R., Shin J.M., Kang A.R., il Lee K., Song S., Kim Y.B., Han S.B., Chung H.M., et al. Placenta-derived mesenchymal stem cells improve memory dysfunction in an Aβ1–42-infused mouse model of Alzheimer’s disease. Cell Death Dis. 2013;4:e958. doi: 10.1038/cddis.2013.490. PubMed DOI PMC

Eichenbaum H., Stewart C., Morris R.G. Hippocampal representation in place learning. J. Neurosci. 1990;10:3531–3542. PubMed PMC

Buzsaki G., Moser E.I. Memory, navigation and theta rhythm in the hippocampal-entorhinal system. Nat. Neurosci. 2013;16:130–138. doi: 10.1038/nn.3304. PubMed DOI PMC

Sasaki T., Leutgeb S., Leutgeb J.K. Spatial and memory circuits in the medial entorhinal cortex. Curr. Opin. Neurobiol. 2015;32:16–23. doi: 10.1016/j.conb.2014.10.008. PubMed DOI PMC

Huntley J.D., Howard R.J. Working memory in early Alzheimer’s disease: A neuropsychological review. Int. J. Geriatr. Psychiatry. 2010;25:121–132. doi: 10.1002/gps.2314. PubMed DOI

Micotti E., Paladini A., Balducci C., Tolomeo D., Frasca A., Marizzoni M., Filibian M., Caroli A., Valbusa G., Dix S., et al. Striatum and entorhinal cortex atrophy in ad mouse models: Mri comprehensive analysis. Neurobiol. Aging. 2015;36:776–788. doi: 10.1016/j.neurobiolaging.2014.10.027. PubMed DOI

Yeh C.Y., Vadhwana B., Verkhratsky A., Rodriguez J.J. Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer’s disease. ASN Neuro. 2011;3:271–279. doi: 10.1042/AN20110025. PubMed DOI PMC

Yeh C.Y., Verkhratsky A., Terzieva S., Rodriguez J.J. Glutamine synthetase in astrocytes from entorhinal cortex of the triple transgenic animal model of Alzheimer’s disease is not affected by pathological progression. Biogerontology. 2013;14:777–787. doi: 10.1007/s10522-013-9456-1. PubMed DOI

Kulijewicz-Nawrot M., Sykova E., Chvatal A., Verkhratsky A., Rodriguez J.J. Astrocytes and glutamate homoeostasis in Alzheimer’s disease: A decrease in glutamine synthetase, but not in glutamate transporter-1, in the prefrontal cortex. ASN Neuro. 2013;5:273–282. doi: 10.1042/AN20130017. PubMed DOI PMC

Olabarria M., Noristani H.N., Verkhratsky A., Rodriguez J.J. Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer’s disease mouse model: Mechanism for deficient glutamatergic transmission? Mol. Neurodegener. 2011;6 doi: 10.1186/1750-1326-6-55. PubMed DOI PMC

Rodriguez J.J., Jones V.C., Tabuchi M., Allan S.M., Knight E.M., LaFerla F.M., Oddo S., Verkhratsky A. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer’s disease. PLoS ONE. 2008;3:152. doi: 10.1371/journal.pone.0002935. PubMed DOI PMC

Rodriguez J.J., Jones V.C., Verkhratsky A. Impaired cell proliferation in the subventricular zone in an Alzheimer’s disease model. Neuroreport. 2009;20:907–912. doi: 10.1097/WNR.0b013e32832be77d. PubMed DOI

Paul G., Anisimov S.V. The secretome of mesenchymal stem cells: Potential implications for neuroregeneration. Biochimie. 2013;95:2246–2256. doi: 10.1016/j.biochi.2013.07.013. PubMed DOI

Chen L., Qiu R., Xu Q. Mesenchymal stem cell therapy for neurodegenerative diseases. J. Nanosci. Nanotechnol. 2014;14:969–975. doi: 10.1166/jnn.2014.9126. PubMed DOI